Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-06-02

Clinical Trial Update: Niacin Skin Flush Response in Patients With Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

Completion of a Phase 2/Phase 3 trial evaluating the niacin skin flush response in schizophrenia patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Niacin (nicotinic acid)

Snippet

Sponsor: Isfahan University of Medical Sciences | Conditions: Schizophrenia | Phase 2, Phase 3 | Status: COMPLETED